19 May 2016
Results of study focusing on miR-31-3p expression in patients enrolled in FIRE-3 trial to be presented during ASCO 2016

The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). (…) »